At a meeting held on Friday 27 May 2022, the National Advisory Committee on Vaccination of the Ministry of Health, recommended that for the prevention of monkeypox, the vaccinia Ankara vaccine (MVA-BN) (Imvanex), which has been licensed by the European Medicines Agency (EMA) in 2013, can be used for the prevention of smallpox and which is recommended in a two-dose regimen. This vaccine is internationally recommended for the prevention and treatment of monkeypox (reported efficacy 85%).
It is recommended that this vaccine is available for targeted administration to specific high-risk groups, such as:
- health professionals who will be called upon to manage possible suspected or confirmed cases, before or after exposure,
- to individuals, close contacts of a confirmed case, after exposure.
It is recommended as administered within 4 days of the date of exposure to prevent the occurrence of disease.
The National Advisory Committee on Vaccination, in collaboration with the Infectious Disease Surveillance and Control Unit of the Medical and Public Health Services of the Ministry of Health, is monitoring epidemiological data and reserves the right to vary the plan according to developments.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source
